Therefore, a phase 2B clinical trial has been investigated to examine whether pegbelfermin (a novel long-acting FGF21) has therapeutic effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) [31]. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.